Harmony Biosciences: Q4 WAKIX revenue ~$201M, FY2024 ~$714M; guides 2025 $820-860M

Harmony Biosciences Holdings, Inc.

2024-FY EPS reported $2.51 revenue$714,734,000

Preliminary Q4 2024 net product revenue ~$201M (vs $168.4M Q4 2023); FY2024 ~$714M (vs $582M, +23% YoY).
2025 net revenue guidance of $820-860M, implying continued growth toward $1B+ opportunity.
Pipeline catalysts: FDA decision on pitolisant sNDA for idiopathic hypersomnia expected Q1 2025; potential approval in 2025.
Phase 3 topline data for ZYN002 in Fragile X syndrome expected Q3 2025; Pitolisant-HD Phase 3 in narcolepsy to start Q4 2025.
Average patients on WAKIX increased to ~7,100 in Q4 2024, up ~300 sequentially.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.